INNOVENT BIO (01801.HK) -2.050 (-2.534%) Short selling $391.98M; Ratio 32.259% opened 6.88% higher today, hitting an intraday peak of HKD82.4. It last quoted at HKD80.65, up 7.75%, with a turnover of 5.4011 million shares, involving HKD438 million.INNOVENT BIO announced that the Group entered into a strategic global licensing and collaboration agreement with Pfizer Inc. (PFE.US) for the research and development of 12 promising breakthrough early-stage and de novo cancer medicines. Related News M Stanley: Risk-Reward of China Biotech Stocks to Improve in 2H2026Pursuant to the Agreement, Innovent will receive a US$650 million upfront payment and is eligible for up to US$9.85 billion in development, regulatory and commercial milestone payments, bringing the total value of the deal to up to US$10.5 billion. The collaboration spans a portfolio of 12 oncology programs, comprising eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs. According to the Agreement, Innovent will conduct development of these programs through Phase 1 clinical study powered by its proprietary discovery engine and robust early clinical capabilities, after which Pfizer will lead the global development. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-02 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)Related News M Stanley Ratings and TPs on China Biotech Stocks
AASTOCKS Financial News